BACKGROUND: Blood @entity413 control is fundamental albeit not enough to prevent @entity2412 . @entity5735 ( @entity5735 ) inhibitors are effective in improving metabolic parameters in @entity1 with @entity6 ( @entity6 ) but little is known about its cardiovascular effects. We compared the @entity5735 inhibitor @entity12350 with bedtime NPH insulin (NPH) as add-on therapy in @entity1 with @entity6 , aiming to ascertain which drug would have additional cardioprotective effects. METHODS: Thirty-five @entity6 @entity1 inadequately controlled with @entity2449 plus @entity5217 were randomized to receive @entity12350 (n   =   18) or NPH (n   =   17) for 24  weeks. Fasting plasma @entity413 , HbA1c, lipid profile, @entity1851 , active glucagon-like peptide (aGLP-1) levels, 24-hour ambulatory blood pressure measurement and comprehensive 2-dimensional echocardiogram were determined before and after treatments. RESULTS: Both @entity12350 and NPH therapies decreased HbA1c levels after 24  weeks. Fasting plasma @entity413 and @entity412 levels decreased in the NPH group whereas only @entity12350 increased aGLP-1 levels. @entity1002 ( @entity1002 ) was detected in 58.6% of twenty-nine @entity1 evaluated. Beneficial effects in @entity1002 were observed in 75% and 11% of @entity1 treated with @entity12350 and NPH, respectively (p   =   0.015). Neither therapy changed @entity1851 or blood pressure. CONCLUSIONS: @entity12350 and bedtime NPH were similarly effective on @entity413 control. Improvement in @entity1002 in @entity6 @entity1 treated with @entity12350 was suggested, probably related to the increase of aGLP-1 levels. Therefore, @entity5735 inhibitor seems to have cardioprotective effects independent of @entity413 control and may have a role in the prevention of @entity13088 .

Left ventricular diastolic function in @entity1 with type 2 @entity6 treated with a XXXX inhibitor- a pilot study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein'] @entity5735 :: ('1803', 'Gene') :: ['DPP-4', 'Dipeptidyl peptidase-4'] @entity6 :: ('MESH:D003920', 'Disease') :: ['type 2 diabetes mellitus', 'T2DM'] @entity13088 :: ('MESH:D058065', 'Disease') :: ['diabetic cardiomyopathy'] @entity5217 :: ('MESH:D005905', 'Chemical') :: ['glyburide'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity12350 :: ('MESH:C496398', 'Chemical') :: ['Sitagliptin', 'sitagliptin'] @entity2412 :: ('MESH:D048909', 'Disease') :: ['diabetic macrovascular complications'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity1002 :: ('MESH:D018487', 'Disease') :: ['Left ventricular diastolic dysfunction', 'LVDD'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['metformin']
@entity5735 :: (1803,Gene) :: ['dipeptidyl peptidase-4']
